High-flow nasal oxygen (HFNO) and non-invasive ventilation (NIV) have been used to manage early acute hypoxemic respiratory failure (AHRF) caused by COVID-19.
As there is no evidence-based recommendation for the selection of HFNO or NIV, staff tend to base their choice on personal preference.
